[Deep venous thrombosis treated by rivaroxaban in a young patient with type Ia carbohydrate-deficient glycoprotein (CDG) syndrome]
- PMID: 29623892
- DOI: 10.1684/abc.2018.1324
[Deep venous thrombosis treated by rivaroxaban in a young patient with type Ia carbohydrate-deficient glycoprotein (CDG) syndrome]
Abstract
Congenital disorders of glycosylation (CDG) are rare inborn diseases of glycan component of N-glycosylated proteins. We report here the case of a 28-year-old patient with CDG syndrome type Ia, who presented with a deep venous thrombosis in the left suro-popliteal vein with no known triggers or antecedents. The patient was treated with rivaroxaban for six months. Blood tests performed after discontinuing anticoagulant treatment showed multiple abnormalities affecting the proteins involved in haemostasis (both coagulation factors and inhibitors), i.e. a combined factor XI, antithrombin and protein C deficiency (35%, 41%, and 42% respectively) associated with a moderate increase of FVIII (179%) and VWFAg (163%) without inflammation. Patient results are here discussed with regard to the limited number of articles addressing haemostasis in this rare disease, as the occurrence of deep venous thrombosis remains uncommon in the literature.
Keywords: CDG syndrome; antithrombin deficiency; deep venous thrombosis; factor XI deficiency; protein C deficiency.
Similar articles
-
Risk assessment of acute vascular events in congenital disorder of glycosylation type Ia.Mol Genet Metab. 2008 Apr;93(4):444-9. doi: 10.1016/j.ymgme.2007.11.006. Epub 2008 Feb 21. Mol Genet Metab. 2008. PMID: 18093857
-
Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation.Mol Genet Metab. 2023 Jun;139(2):107606. doi: 10.1016/j.ymgme.2023.107606. Epub 2023 May 9. Mol Genet Metab. 2023. PMID: 37224763
-
Association between acute complications in PMM2-CDG patients and haemostasis anomalies: Data from a multicentric study and suggestions for acute management.Mol Genet Metab. 2023 Nov;140(3):107674. doi: 10.1016/j.ymgme.2023.107674. Epub 2023 Jul 31. Mol Genet Metab. 2023. PMID: 37542768
-
[Congenital disorder of glycosylation type Ia (CDG Ia) - underdiagnosed entity?].Duodecim. 2016;132(3):253-9. Duodecim. 2016. PMID: 26951030 Review. Finnish.
-
The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia).Biochim Biophys Acta. 2009 Sep;1792(9):827-34. doi: 10.1016/j.bbadis.2009.01.003. Epub 2009 Jan 14. Biochim Biophys Acta. 2009. PMID: 19272306 Review.
Cited by
-
Nutrition interventions in congenital disorders of glycosylation.Trends Mol Med. 2022 Jun;28(6):463-481. doi: 10.1016/j.molmed.2022.04.003. Epub 2022 May 10. Trends Mol Med. 2022. PMID: 35562242 Free PMC article. Review.
-
Treatment Options in Congenital Disorders of Glycosylation.Front Genet. 2021 Sep 10;12:735348. doi: 10.3389/fgene.2021.735348. eCollection 2021. Front Genet. 2021. PMID: 34567084 Free PMC article. Review.
-
Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update.Genet Med. 2020 Feb;22(2):268-279. doi: 10.1038/s41436-019-0647-2. Epub 2019 Sep 19. Genet Med. 2020. PMID: 31534212 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical